Oncodrex Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $564K

  • Investors
  • 2

Oncodrex General Information

Description

Operator of a cancer diagnostics company designed to develop a colorectal cancer screening test. The company's technology is based on the discovery of two biomarkers that are present in high concentrations in the peripheral blood of cyclic redundancy check patients, enabling patients to avail of a cost-effective, highly sensitive, and reliable test for detecting colorectal cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Corporate Office
  • 158 Commerce Drive
  • Winnipeg, Manitoba R3P 0Z6
  • Canada
+1 (204)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 158 Commerce Drive
  • Winnipeg, Manitoba R3P 0Z6
  • Canada
+1 (204)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncodrex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 30-Jun-2019 $564K Completed Clinical Trials - General
2. Angel (individual) 14-Feb-2018 Completed Clinical Trials - General
1. Angel (individual) 01-Aug-2017 Completed Clinical Trials - General
To view Oncodrex’s complete valuation and funding history, request access »

Oncodrex Patents

Oncodrex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3023175-A1 N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer Pending 03-May-2016
EP-3452831-A1 N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer Active 03-May-2016
EP-3452831-A4 N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer Active 03-May-2016
EP-3452831-B1 N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer Active 03-May-2016
US-12024748-B2 N-myristoyltransferase (nmt)1, nmt2 and methionine aminopeptidase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for adenomatous polyps and early detection of colorectal cancer Active 03-May-2016 C12Q1/6883
To view Oncodrex’s complete patent history, request access »

Oncodrex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncodrex Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovate Manitoba Accelerator/Incubator
Valhalla Private Capital Angel Group Minority
To view Oncodrex’s complete investors history, request access »

Oncodrex FAQs

  • When was Oncodrex founded?

    Oncodrex was founded in 2014.

  • Where is Oncodrex headquartered?

    Oncodrex is headquartered in Winnipeg, Canada.

  • What is the size of Oncodrex?

    Oncodrex has 2 total employees.

  • What industry is Oncodrex in?

    Oncodrex’s primary industry is Biotechnology.

  • Is Oncodrex a private or public company?

    Oncodrex is a Private company.

  • What is Oncodrex’s current revenue?

    The current revenue for Oncodrex is .

  • How much funding has Oncodrex raised over time?

    Oncodrex has raised $25K.

  • Who are Oncodrex’s investors?

    Innovate Manitoba and Valhalla Private Capital have invested in Oncodrex.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process